Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ATNX - Athenex Inc


Close
0.2031
-0.062   -30.527%

Share volume: 0
Last Updated: Wed 24 May 2023 10:00:00 PM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$0.27
-0.06
-23.39%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
26%
Profitability 18%
Dept financing 23%
Liquidity 11%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.20
P/E Ratio 
0.00
DAY RANGE
$0.20 - $0.20
EPS 
-$15.81
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
8.663 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Johnson Lau
Region: US
Website: https://www.athenex.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Recent news